Posted by Michael Wonder on 31 Mar 2025
Imfinzi approved in the US as first and only peri-operative immunotherapy for patients with muscle-invasive bladder cancer
31 March 2025 - Based on NIAGARA Phase 3 trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neo-adjuvant chemotherapy alone
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neo-adjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer.
